Tretinoin (NSC 122758)

InformationTretinoin (NSC 122758) Tretinoin (NSC 122758, Retinoic acid, All-trans Retinoic Acid, ATRA, Vitamin A acid, Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Stieva-A), which is a ligand for both the retinoic acid receptor (RAR) and the retinoid X recepIn vitroTretinoin prevents the cytotoxicity of H2O2 in cultured human mesangial cells by increasing both the catalase activity and the reduced glutathione content, which are dose- and time-dependent changes. Tretinoin-incubated mesangial cells leads to increased levels of catalase mRNA and gamma-glutamyl-cysteine synthetase (catalytic subunit) mRNA, the latter being the rate-limiting step in de novo reduced glutathione synthesis. Tretinoin upregulates matrix metalloproteinase-13 and matrix metalloproteinase-8 in human keloid-derived fibroblasts.In vivoTretinoin-treated old male Fischer 344 rats have 30% lower protein content in the renal cortex than control old rats, this effect may depend on the inhibition of the expression of tumor necrosis factor-beta1, a matrigenic cytokine, and osteopontin, a protein with cell adhesive and chemotactic properties. Tretinoin has the ability to prevent the major steroid-induced biomechanical changes in hairless mouse dermal connective tissue that contribute to atrophy. Tretinoin combined with imiquimod leads to faded tattoos and moderate clearance of pigment on histopathology in the guinea pig. Tretinoin increases fibroplastic proliferation in the Skin incisions were made in 45 CD-1 mice, but the production of collagen was diminished.Cell Datacell lines：HCT 116 cellsConcentrations：Incubation Time：Powder Purity:≥97%. Specification: 10mM in DMSO Molecular Formula: C20H28O2 Molecular Weight: 300.4